Richtig G, Wolf M, Schulter G, et al. Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab. SMR 2017, P01-15.
Adjuvant pembrolizumab bij volledig gereseceerd stadium IIB/IIC-melanoom
jul 2022 | Dermato-oncologie, Immuuntherapie